Total trials
1,644
Active
363
Phase 3
76
Total enrollment
43,838,650
Pipeline matrix
Showing 40 of 168 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Levothyroxine Sodium (LT4) | — | — | — | — | 2 | ||
| Vancomycin | — | — | — | — | 2 | ||
| Spironolactone | — | — | — | — | 2 | ||
| Inactivated influenza vaccine | — | — | — | — | — | 1 | |
| Pharmacotherapy with paroxetine or venlafaxine XR | — | — | — | — | — | 1 | |
| Seasonal influenza vaccine | — | — | — | — | — | 1 | |
| Depot medroxyprogesterone acetate | — | — | — | — | — | 1 | |
| Influenza vaccination | — | — | — | — | — | 1 | |
| Piperacillin-tazobactam | — | — | — | — | — | 1 | |
| Cefepime | — | — | — | — | — | 1 | |
| Sitagliptin 100mg | — | — | — | — | — | 1 | |
| Diphenhydramine, 25 mg | — | — | — | — | — | 1 | |
| Diphenhydramine, 50 mg | — | — | — | — | — | 1 | |
| Doxepin, 3 mg | — | — | — | — | — | 1 | |
| Doxepin, 6 mg | — | — | — | — | — | 1 | |
| Trazodone, 50 mg | — | — | — | — | — | 1 | |
| Trazodone, 100 mg | — | — | — | — | — | 1 | |
| Zolpidem, 5 mg | — | — | — | — | — | 1 | |
| Zolpidem, 10 mg | — | — | — | — | — | 1 | |
| Doxycycline Hyclate | — | — | — | — | — | 1 | |
| Nexplanon 68 MG Drug Implant | — | — | — | — | — | 1 | |
| Nanozyme treatment | — | — | — | — | — | 1 | |
| Control | — | — | — | — | — | 1 | |
| XR-NTX 380 mg, intramuscular | — | — | — | — | — | 1 | |
| FDG | — | — | — | — | 2 | ||
| Abatacept | — | — | — | — | 2 | ||
| [18F]-PI-2620 | — | — | — | — | — | 1 | |
| Aspirin 162 mg | — | — | — | — | — | 1 | |
| Aspirin 81mg | — | — | — | — | — | 1 | |
| Guselkumab | — | — | — | — | — | 1 | |
| Golimumab | — | — | — | — | — | 1 | |
| Ethanol | — | — | — | — | — | 1 | |
| Isocaloric dextrose placebo | — | — | — | — | — | 1 | |
| 18F-AV-1451 | — | — | — | — | — | 1 | |
| 200mg mifepristone and 800mg misoprostol | — | — | — | — | — | 1 | |
| Varenicline | — | — | 14 | ||||
| Nicotine patch | — | — | — | — | 2 | ||
| Tocilizumab | — | — | — | — | 3 | ||
| Azathioprine | — | — | — | — | — | 2 | |
| Adalimumab | — | — | — | — | 3 |
128 more active programs hidden
Next readouts
- 2022-01-05
- 2022-09-08
- 2024-05-20
- 2024-06-30
- 2025-02-27
- 2025-10-08
- 2025-12-01
- 2026-02-14
- 2026-04-30
- 2026-06
Top conditions
- Obesity69
- Depression38
- Healthy36
- Hypertension31
- Diabetes28
- Stroke23
- Heart Failure22
- Anxiety21
Frequently asked questions about University of Pennsylvania
- How many clinical trials does University of Pennsylvania have on ClinicalTrials.gov?
- University of Pennsylvania is listed as the lead sponsor on 1,644 clinical trials in ClinicalTrials.gov, 363 of which are currently active (recruiting, enrolling, or ongoing).
- How many of University of Pennsylvania's trials are in Phase 3?
- 76 of University of Pennsylvania's trials are in Phase 3, spread across 168 active drug programs.
- What therapeutic areas does University of Pennsylvania focus on?
- University of Pennsylvania's most-studied conditions on ClinicalTrials.gov are Obesity, Depression, Healthy, Hypertension, Diabetes.
- When are University of Pennsylvania's next clinical trial readouts?
- University of Pennsylvania has 10 upcoming primary-completion readouts tracked here; the soonest is “Comparison of the Short-Term Effect of Dietary Carbohydrate Restriction Versus Exogenous Ketone Supplementation on Myocardial Glucose Suppression and Timing to Achieve a State of Ketosis Using FDG PET/CT Serial Imaging”, expected around 2022-01-05.